The Ipsen Investment Case

Oncology Key ongoing clinical-trial highlights Trial Cabometyx CONTACT-02 Phase III NCT04446117 Cabometyx Phase lb NCT03170960 Onivyde NAPOLI-3 Phase III NCT04083235 Onivyde RESILIENT Phase III NCT03088813 IPSEN Innovation for patient care Population Patients 2L CRPC 580 Solid tumors 1,732 Design Second novel hormonal therapy (abiraterone and prednisone or enzalutamide) or Cabometyx + atezolizumab Cabometyx+atezolizumab Endpoints Primary: OS, PFS Additional endpoints: ORR, prostate-specific antigen response rate and duration of response Primary: maximum tolerated dose / recommended dose, ORR Status Data anticipated 2023 Recruiting Secondary: safety Nab-paclitaxel + gemcitabine or 1L PDAC 750 Onivyde + 5-FU/LV + oxaliplatin Primary: OS Secondary: PFS, ORR, Data anticipated 2023 Topotecan 2L SCLC 461 or Onivyde safety Primary: OS Secondary: PFS, ORR, safety Data anticipated H2 2022 28

View entire presentation